Ad26.Mos.HIV

BIOLOGICAL4 trials

Sponsors

Janssen Vaccines & Prevention B.V.

Conditions

HealthyHuman Immunodeficiency Virus

Phase 1

Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) Prevention

CompletedNCT02315703

Janssen Vaccines & Prevention B.V.Healthy

Start: 2014-12-22End: 2022-03-28Updated: 2025-02-04

Safety, Tolerability and Immunogenicity Study of Different Vaccine Schedules With Ad26.Mos.HIV and Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults

CompletedNCT02685020

Janssen Vaccines & Prevention B.V.Healthy

Start: 2016-03-28End: 2019-01-03Updated: 2025-02-03

Safety, Tolerability and Immunogenicity Study of Different Vaccine Regimens of Trivalent Ad26.Mos.HIV or Tetravalent Ad26.Mos4.HIV Along With Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults

CompletedNCT02788045

Janssen Vaccines & Prevention B.V.Healthy

Start: 2016-07-08End: 2022-04-25Updated: 2025-05-25

Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults

CompletedNCT02919306

Janssen Vaccines & Prevention B.V.Human Immunodeficiency Virus

Start: 2016-09-30End: 2018-09-30Updated: 2025-02-04

Related Papers

ALVAC-prime and monomeric gp120 protein boost induces distinct HIV-1 specific humoral and cellular responses compared with adenovirus-prime and trimeric gp140 protein boost

PLOS Global Public Health2025-04-11

The Question of HIV Vaccine: Why Is a Solution Not Yet Available?

Journal of Immunology Research2024-01-0112 citations

Paradoxically Greater Persistence of HIV RNA-Positive Cells in Lymphoid Tissue When ART Is Initiated in the Earliest Stage of Infection

The Journal of Infectious Diseases2022-03-0912 citations

Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study.

2020-10-0175 citations

Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption.

2020-03-2356 citations

Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22).

2020-02-1719 citations

Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).

2018-07-06276 citations